13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001792126
Total reported value
$2.3B
$2.3B
53 檔
21.6%
As reported in its official Q2 2024 Form 13F filing, Logos Global Management LP's tracked investment portfolio stood at $2.3B with 53 total positions.
During Q2 2024, Logos Global Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 14.91% | — | — | |
| 2 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 8.26% | — | -59.38% | |
| 3 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 7.40% | — | +200.00% | |
| 4 | GPCR | Structure Therapeutics Inc | Stock-Other | 4.90% | -0.04% | +32.47% | |
| 5 | IDYA | Ideaya Biosciences Inc | Stock-Other | 4.80% | -0.93% | +13.33% | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.67% | — | — | |
| 7 | ✓ | Merus N V | Stock-Other | 4.05% | — | — | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.75% | -4.07% | — | |
| 9 | IRON | Disc Medicine Inc | Stock-Other | 3.35% | +0.97% | — | |
| 10 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.83% | +0.61% | -11.38% | |
| 11 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 2.79% | -0.66% | -26.80% | |
| 12 | VERA | Vera Therapeutics Inc | Stock-Other | 2.76% | +4.06% | NEW | |
| 13 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.65% | +0.84% | — | |
| 14 | JANX | Janux Therapeutics Inc | Stock-Other | 2.53% | -0.69% | EXIT | |
| 15 | XNCR | Xencor Inc | Stock-Other | 2.28% | — | +130.77% | |
| 16 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 2.26% | — | — | |
| 17 | ANNX | Annexon Inc | Stock-Other | 1.89% | +0.37% | NEW | |
| 18 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 19 | DSGN | Design Therapeutics Inc | Stock-Other | 1.36% | +0.83% | — | |
| 20 | IMVT | Immunovant Inc | Stock-Other | 1.22% | -0.23% | -67.61% | |
| 21 | NUVL | Nuvalent Inc-a | Stock-Other | 1.19% | — | — | |
| 22 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.18% | -0.14% | — | |
| 23 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.15% | — | — | |
| 24 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.14% | — | — | |
| 25 | ERAS | Erasca Inc | Stock-Other | 1.12% | +0.57% | — | |
| 26 | ELVN | Enliven Therapeutics Inc | Stock-Other | 1.12% | -1.02% | -62.20% | |
| 27 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.09% | — | +130.00% | |
| 28 | ✓ | Engene Holdings Inc | Stock-Other | 0.91% | — | +50.00% | |
| 29 | CYBNEUR | Cybin Inc | Stock-Other | 0.87% | — | — | |
| 30 | SKYE | Skye Bioscience Inc | Stock-Other | 0.84% | — | — | |
| 31 | ✓ | Elevation Oncology Inc | Stock-Other | 0.84% | — | +285.00% | |
| 32 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.75% | +1.17% | -84.68% | |
| 33 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.75% | — | +50.00% | |
| 34 | BHVN | Biohaven Ltd. | Stock-Other | 0.70% | — | — | |
| 35 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.68% | -0.09% | — | |
| 36 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.67% | +0.08% | +27.27% | |
| 37 | RCKT | Rocket Pharmaceuticals Inc | Stock-Other | 0.61% | — | -73.08% | |
| 38 | CMPS | Compass Pathways PLC | Stock-Other | 0.56% | +1.37% | NEW | |
| 39 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.54% | -0.06% | — | |
| 40 | LCTX | Lineage Cell Therapeutics In | Stock-Other | 0.38% | — | -24.80% | |
| 41 | ATYR | Atyr Pharma Inc | Stock-Other | 0.38% | — | -3.23% | |
| 42 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.37% | — | -77.73% | |
| 43 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.35% | — | — | |
| 44 | NXTCEUR | Nextcure Inc | Stock-Other | 0.32% | — | +29.87% | |
| 45 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.24% | — | -21.54% | |
| 46 | ALLKGUSD | Allakos Inc | Stock-Other | 0.23% | — | — | |
| 47 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.23% | — | -72.22% | |
| 48 | APLT | Applied Therapeutics Inc | Stock-Other | 0.21% | — | -55.56% | |
| 49 | RNAC | Cartesian Therapeutics Inc | Stock-Other | 0.20% | — | — | |
| 50 | ✓ | Stock-Other | 0.14% | — | — |
According to official SEC Form 13F filings, Logos Global Management LP reported a total U.S. public equity portfolio value of $2.3B across 53 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including XBI, SRPT, APLSUSD) accounted for 21.6% of total reported equity market value during Q2 2024.
During Q2 2024, Logos Global Management LP's top holdings by market value included XBI (14.9%)、SRPT (8.3%)、APLSUSD (7.4%). The largest single position, XBI, represented 14.9% of total portfolio value.
In Q2 2024, Logos Global Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.